Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology
Disease Category: Breast Cancer

Trial Information

A Phase I/II Study of HKI-272 in Combination with Vinorelbine in Subjects with Solid Tumors and Metastatic Breast Cancer

You have been asked to participate in this research study because you have metastatic breast cancer. The purpose of this study is to evaluate the safety and effectiveness of HKI-272 (neratinib) when it is given in combination with Vinorelbine. For this reason, test article is considered both neratinib and Vinorelbine. Repeated blood samples will be taken before and after neratinib and Vinorelbine are given to study the levels of neratinib and Vinorelbine that stay in the body over time. Your treatment on this study is estimated to continue for 36 weeks, (about 9 months). If your cancer is stable (has not gotten worse) and your study doctor recommends that you continue on the study, you may continue to receive study drugs beyond 9 months. After your treatment on this study is over, your medical condition will continue to be followed on study for approximately 6 weeks.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.